Results 121 to 130 of about 147,528 (279)
Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes
Large‐cell transformation of mycosis fungoides is rare with poor prognosis. Presenting over 20 years of data, this retrospective study of 83 patients demonstrated a median overall survival (mOS) of 3.5 years. However, prognostic differences in three clinical subgroups were suggested: unifocal, multifocal, extra‐cutaneous (mOS: 4.6, 2.5, 1.1 years ...
Philippa Johnstone+9 more
wiley +1 more source
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu+17 more
wiley +1 more source
Cutaneous involvement in angioimmunoblastic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive non-Hodgkin′s nodal peripheral T-cell lymphoma characterized by general lymphadenopathy, night sweats, fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia, and cutaneous ...
Papadavid Evangelia+5 more
doaj
Extranodal natural killer/T-cell lymphoma with paraneoplastic eosinophilic myositis
Extranodal natural killer/T-cell lymphoma is a rare Epstein-Barr virus-associated aggressive lymphoma commonly involving the nasal and upper aerodigestive tract and, less commonly, extranodal sites such as skin and gastrointestinal tract.
Jayati Mallick+2 more
doaj
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source
Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis
Australasian Journal of Dermatology, EarlyView.
Mizuho Namba+6 more
wiley +1 more source
GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng+3 more
wiley +1 more source
Lichen Planus Follicularis Tumidus
Australasian Journal of Dermatology, EarlyView.
A. I. Oloruntoba+2 more
wiley +1 more source
Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T‐Cell Leukemia/Lymphoma
UMAP projection of CD4 T cells from ATLL patients specified a CD48‐deficient cluster, in which YY1 and EZH2 are upregulated. ABSTRACT The clinical and genetic presentation of adult T‐cell leukemia/lymphoma (ATLL) ranges from indolent to aggressive, making it difficult to identify common therapeutic targets.
Takuya Shimizu+5 more
wiley +1 more source